#1Third Quarter 2021 Corporate update and financial results November 9, 2021 ‒‒‒‒‒‒‒ BIONTECH#2This Slide Presentation Includes Forward-looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY® where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors after BioNTech's initial sales to national governments; the extent to which initial or booster doses of a COVID-19 vaccine continue to be necessary in the future; competition from other COVID-19 vaccines or related to BioNTech's other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; the initiation, timing, progress, results, and cost of BioNTech's research and development programs and BioNTech's current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and BioNTech's research and development programs; the timing of and BioNTech's ability to obtain and maintain regulatory approval for BioNTech's product candidates; the collaboration between BioNTech and Pfizer to develop a COVID-19 vaccine (including a potential booster dose of BNT162b2 and/or a potential booster dose of a variation of BNT 162b2 having a modified mRNA sequence); the ability of BNT 162b2 to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of the COVID-19 pandemic on BioNTech's development programs, supply chain, collaborators and financial performance; unforeseen safety issues and claims for personal injury or death arising from the use of BioNTech's COVID-19 vaccine and other products and product candidates developed or manufactured by us; BioNTech's ability to progress BioNTech's Malaria, Tuberculosis and HIV programs, including timing for selecting clinical candidates for these programs and the commencement of a clinical trial, as well as any data readouts; the nature of the collaboration with the African Union and the Africa CDC; the nature and duration of support from WHO, the European Commission and other organizations with establishing infrastructure; the development of sustainable vaccine production and supply solutions on the African continent and the nature and feasibility of these solutions; BioNTech's estimates of research and development revenues, commercial revenues, cost of sales, research and development expenses, sales and marketing expenses, general and administrative expenses, capital expenditures, income taxes, shares outstanding; BioNTech's ability and that of BioNTech's collaborators to commercialize and market BioNTech's product candidates, if approved, including BioNTech's COVID-19 vaccine; BioNTech's ability to manage BioNTech's development and expansion; regulatory developments in the United States and foreign countries; BioNTech's ability to effectively scale BioNTech's production capabilities and manufacture BioNTech's products, including BioNTech's target COVID-19 vaccine production levels, and oBioNTech'sur product candidates; and other factors not known to BioNTech at this time. In some cases, forward-looking statements can be identified by terminology such as “will," "may," "should," "expects," "intends," "plans,” “aims,” “anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this quarterly report are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's quarterly report for the three and nine months ended September 30, 2021 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at https://www.sec.gov/. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any for-ward-looking statements contained in this quarterly report in the event of new information, future developments or otherwise. These forward-looking statements are based on BioNTech's current expectations and speak only as of the date hereof. 2 BIONTECH#3Safety Information AUTHORIZED USE IN THE U.S.: The Pfizer-BioNTech COVID19 Vaccine is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. IMPORTANT SAFETY INFORMATION FROM U.S. FDA EMERGENCY USE AUTHORIZATION PRESCRIBING INFORMATION: Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine Monitor Pfizer-BioNTech COVID-19 Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html) Reports of adverse events following use of the Pfizer-BioNTech COVID-19 Vaccine under EUA suggest increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The decision to administer the Pfizer-BioNTech COVID-19 Vaccine to an individual with a history of myocarditis or pericarditis should take into account the individual's clinical circumstances Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine The Pfizer-BioNTech COVID-19 Vaccine may not protect all vaccine recipients ● ● ● ● ● ● ● ● ● ● ● ● ● ● . In clinical studies, adverse reactions in participants 16 years of age and older included pain at the injection site (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%), injection site swelling (10.5%), injection site redness (9.5%), nausea (1.1%), malaise (0.5%), and lymphadenopathy (0.3%), following administration of the primary series In a clinical study, adverse reactions in adolescents 12 through 15 years of age included pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), injection site redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%), following administration of primary series In a clinical study, adverse reactions in adults 18 through 55 years of age following administration of a booster dose were pain at the injection site (83.0%), fatigue (63.7%), headache (48.4%), muscle pain (39.1%), chills (29.1%), joint pain (25.3%), lymphadenopathy (5.2%), nausea (0.7%), decreased appetite (0.3%), rash (0.3%), and pain in extremity (0.3%) Following administration of the Pfizer-BioNTech COVID-19 Vaccine, the following have been reported outside of clinical trials: severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions, diarrhea, vomiting, and pain in extremity (arm) and syncope myocarditis and pericarditis Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Pfizer-BioNTech COVID-19 Vaccine Available data on Pfizer-BioNTech COVID-19 Vaccine administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy Data are not available to assess the effects of Pfizer-BioNTech COVID-19 Vaccine on the breastfed infant or on milk production/excretion There is no information on the co-administration of the Pfizer-BioNTech COVID-19 Vaccine with other vaccines. . An overall review of adverse reactions reported in the study following the Pfizer-BioNTech COVID-19 Vaccine heterologous booster dose did not identify any new safety concerns, as compared with adverse reactions reported following a Pfizer-BioNTech COVID-19 Vaccine primary series doses or homologous booster dose Vaccination providers must report Adverse Events in accordance with the Fact Sheet to VAERS online at https://vaers.hhs.gov/reportevent.html. For further assistance with reporting to VAERS call 1-800-822-7967. The reports should include the words "Pfizer-BioNTech COVID-19 Vaccine EUA" in the description section of the report Vaccination providers should review the Fact Sheet for Information to Provide to Vaccine Recipients/Caregivers and Mandatory Requirements for Pfizer-BioNTech COVID-19 Vaccine Administration Under Emergency Use Authorization Before administration of Pfizer-BioNTech COVID-19 Vaccine, please see Emergency Use Authorization (EUA) Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) including Full EUA Prescribing Information available at www.cvdvaccine-us.com 3 BIONTECH#4Safety Information COMIRNATYⓇ (COVID-19 mRNA Vaccine) has been granted conditional marketing authorisation by the European Medicines Agency to prevent coronavirus disease 2019 (COVID-19) in people from 12 years of age. EMA's human medicines committee (CHMP) has completed its rigorous evaluation of COMIRNATY®, concluding by consensus that sufficiently robust data on the quality, safety and efficacy of the vaccine are now available. Important safety information Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with a known hypersensitivity to the active substance or to any of the excipients listed Events of anaphylaxis have been reported. Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic reaction following the administration of the vaccine Very rare cases of myocarditis and pericarditis have been observed following vaccination with Comirnaty. These cases have primarily occurred within 14 days following vaccination, more often after the second vaccination, and more often in younger men. Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions (e.g. dizziness, palpitations, increases in heart rate, alterations in blood pressure, tingling sensations and sweating) may occur in association with the vaccination process itself. It is important that precautions are in place to avoid injury from fainting Vaccination should be postponed in individuals suffering from acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not delay vaccination As with other intramuscular injections, the vaccine should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as haemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals The efficacy, safety and immunogenicity of the vaccine has not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of COMIRNATYⓇ may be lower in immunosuppressed individuals. The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials As with any vaccine, vaccination with COMIRNATY® may not protect all vaccine recipients. Individuals may not be fully protected until 7 days after their second dose of vaccine. Comirnaty has no or negligible influence on the ability to drive and use machines. However, some of side effectsm mentioned below, may temporarily affect the ability to drive or use machines. In clinical studies, the most frequent adverse reactions in participants 16 years of age and older that received 2 doses were injection site pain (> 80%), fatigue (> 60%), headache (> 50%), myalgia (> 40%), chills (>30%), arthralgia (> 20%), pyrexia and injection site swelling (> 10%) and were usually mild or moderate in intensity and resolved within a few days after vaccination. A slightly lower frequency of reactogenicity events was associated with greater age In clinical trials, the most frequent adverse reactions in participants 18 to 55 years of age who received a booster were injection site pain (> 80%), fatigue (> 60%), headache (> 40%), myalgia (> 30%), chills and arthralgia (> 20%). The overall safety profile of COMIRNATY® in adolescents 12 to 15 years of age was similar to that seen in participants 16 years of age and older. The most frequent adverse reactions in adolescents 12 to 15 years of age that received 2 doses were injection site pain (> 90%), fatigue and headache (> 70%), myalgia and chills (> 40%), arthralgia and pyrexia (> 20%) There is limited experience with use of COMIRNATY® in pregnant women. Administration of COMIRNATY® in pregnancy should only be considered when the potential benefits outweigh any potential risks for the mother and foetus. It is unknown whether COMIRNATY® is excreted in human milk. Interactions with other medicinal products or concomitant administration of COMIRNATY® with other vaccines has not been studied. Very rare cases of myocarditis and pericarditis have been observed following vaccination with COMIRNATY® primarily in younger males, after the second dose, within 14 days following vaccination The black equilateral triangle denotes that additional monitoring is required to capture any adverse reactions. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. Side effects can be reported to EudraVigilance [http://www.adrreports.eu/] or directly to BioNTech using email [email protected], telephone +49 6131 9084 0, or our website https://medical information.biontech.de/ 4 BIONTECH#5Agenda Third Quarter 2021 Highlights LO 5 Ugur Sahin COVID-19 Vaccine Update Sean Marett Özlem Türeci Oncology Pipeline Update Özlem Türeci Financial Results Jens Holstein Corporate Update & Outlook Ryan Richardson BIONTECH#6....... ....... 2021 Strong Commercial Performance and Continued Pipeline Expansion HOMINO12 BIONTECH BIONTECH#7BioNTech: A Global Immunotherapy Powerhouse Deep Immunology Expertise Fully Integrated 7 Broad Suite of Novel Technologies Automation & Digitalization Specialized Manufacturing Commercial Capabilities Global Team of 2,800+ ✓ ✓ A Diverse Pipeline of 20+ Candidates ● *as of Nov. 2, 2021: includes doses shipped by collaboration partner Pfizer Next-Generation Immunotherapies & Vaccines Oncology, Infectious Diseases and Beyond Delivered >2 bn doses of COVID-19 vaccine* Initiated 3 randomized Phase 2 clinical trials Initiated 5 first-in-human trials Potential to Launch Multiple Products in the Next 5 Years BIONTECH#8Harnessing the Power of the Immune System to Address Serious Diseases ● 1 MARKETED VACCINE 8 Infectious Disease 1 PHASE 1 PROGRAM Validated mRNA technology • Flexible & adaptable platform • Speed in clinical development ● Global manufacturing network • Large safety database with proven path to regulatory approval Focus on significant global health needs, including COVID- 19¹, malaria², HIV³, TB³, influenza¹ 9 PRECLINICAL PROGRAMS Broaden Disease Horizon: ● ¹Collaboration with Pfizer; 2Collaboration with KENUP Foundation; ³Collaboration with Bill & Melinda Gates Foundation ● ● 15 PROGRAMS IN 19 CLINICAL TRIALS Oncology 4 RANDOMIZED PHASE 2 PROGRAMS Sophisticated toolbox of technologies across 4 drug classes Diverse and complementary modes of action Novel therapeutic targets Potential for synergistic combinations Single agent objective responses in multiple Phase 1 trials. Focus on broad range of solid tumors with the potential to improve treatment paradigms Autoimmune and inflammatory diseases, regenerative medicine BIONTECH#9Strong Performance in the Third Quarter of 2021 Corporate Updates Reported Q3 total revenues of €6.1 bn Acquisition of PhagoMed: Expansion into new class of precision antibacterials Third Quarter 2021 Highlights 9 Continued Pipeline Advancement RANDOMIZED PHASE 2 TRIAL STARTS iNeST: autogene cevumeran (BNT 122/ RO7198457; adjuvant treatment of ctDNA+, resected Stage II/III colorectal cancer) FIRST-IN-HUMAN PHASE 1 TRIAL STARTS mRNA vaccine: BNT 161 (influenza) COVID-19 Vaccine* Delivered >2 bn doses to more than 152 countries and territories worldwide, including low- and middle-income countries* ● ● ● Expect to deliver up to 2.5 bn doses in 2021 U.S. government purchased an additional 50 m pediatric doses (5 to <12 years of age) CPI R/R, checkpoint inhibitor resistant or refractory "As of November 2, 2021: includes doses shipped by collaboration partner Pfizer SITC PRESENTATIONS Safety and preliminary efficacy signals for 6 oncology programs across 3 therapeutic platforms. BNT111 GRANTED FDA ORPHAN DESIGNATION IN CPI R/R MELANOMA BLA APPROVAL IN U.S. BOOSTER DOSE Approved in EU for individuals ≥18 years of age Authorized for ≥65 and high-risk populations in U.S. LABEL EXTENSION ● ● ● Clinical data for children aged 5 to <12 submitted to regulators globally EUA approval in the U.S. for children 5 to <12 BIONTECH#10Agenda Third Quarter 2021 Highlights 10 Oncology Vaccine Update Pipeline Update COVID-19 Financial Results Corporate Update & Outlook BIONTECH#11A Leading Provider of COVID-19 Vaccines Globally Ensuring Equitable Vaccine Access to Children and Low & Lower Middle-Income Countries U.S. exercised final purchase option under existing contract with purchase of 50 m pediatric doses Includes vaccines for children under 5 years of age • Brings total U.S. vaccine doses secured to 600 m 2 bn doses pledged through end of 2022 to ensure global equitable vaccine access* ● ● ● Plan to initiate construction of state-of-the-art mRNA vaccine manufacturing site in Africa in mid-2022 11 Agreement with U.S. government to provide 1 bn doses for donation. via COVAX to 100 countries, including those in African Union Expanding manufacturing network to Africa and South America Development and implementation of scalable regional manufacturing network in Africa to enable an annual manufacturing capacity of several 100 m vaccine doses As of beginning of November 2021; In combination with contract entered into by Pfizer BIONTECH#12Continued Progress Across Six Key Levers to Expand COVID-19 Vaccine Reach Increased Manufacturing Capacity Global Clinical Program to Generate Data and Support Label Expansion to Additional Populations Regulatory Advancement Across All Geographies Optimize Formulations to Further Simplify Access Worldwide Addressing Waning Immune Reponses Preemptive Prototype Approach to Addressing SARS-CoV-2 Variants 12 ● ● ● ● ● BLA approval in the Unites States for BNT162b2 to prevent COVID-19 in individuals 16 and older Booster dose • U.S. FDA authorization for emergency use in individuals 65 and older, individuals 18-64 at high risk of severe COVID-19, or with frequent exposure, and for third dose in severely immunocompromised individuals ● EC approval in individuals ≥ 18 years of age and for third dose in severely immunocompromised people following positive opinion from EMA CHMP Label extension ● ● Expect to manufacture 2.7 bn to 3 bn doses by end of 2021 Global COVID-19 vaccine supply chain and manufacturing network with more than 20 manufacturing facilities across four continents ● Positive safety and efficacy data reported in children aged 5 to <12 Children cohorts 2-5 years and 6 months to 2 years of age: data expected late Q4 2021 or early Q1 2022 Global Phase 2/3 trial in healthy pregnant women ongoing ● Submitted for variation of CMA to EMA in children 5 to <12 EUA granted in U.S. for children 5 to <12 FDA and EMA authorized storage of current vaccine for up to 9 months at -90 to -60 °C New formulation with further simplified handling and optimized storage - up to 10 weeks at 2 to 8 °C - approved by EC, following positive opinion from EMA CHMP Multiple trials ongoing to address need for booster dose of BNT162b2, including a 10,000-participant efficacy study demonstrating 95.6% relative vaccine efficacy against disease after booster dose during period when Delta variant was prevalent strain Generating data for variant-encoding vaccine candidates to support platform approach to emerging SARS-CoV-2 variants BIONTECH#13Clinical Data Support Label Extension of BNT162b2 to Children 5 to 11 Years of Age¹ Robust immune response in children 5 to 11 years one month after the second dose of BNT162b2 ● ● 50% serum neutralizing titer 100,000 10,000 1000 100 10 BNT162b2 10 µg 5-11 years old (n=264) GMFR (95% CI) 118.2 (109.2, 127.9) 10 (9.9, 10.3) I 1198 (1106.1, 1296.6) Before 1 month vaccination after dose 2 BNT162b2 30 μg 16-25 years old (n=253) GMFR (95% CI) 111.4 (101.2, 122.7) 10 (9.8, 10.8) T 1147 (1045.5, 1257.2) Placebo 5-11 years old (n=130) GMFR (95% CI) 1.1 (1.0, 1.2) 10 (10.0, 10.0) 11 (9.7, 11.8) 1 month Before 1 month Before vaccination after dose 2 vaccination after dose 2 Placebo 16-25 years old (n=45) GMFR (95% CI) 1.0 (1.0, 1.0) 10 (10.0, 10.0) 10 (10.0, 10.0) 1 month Before vaccination after dose 2 Two doses of 10µg administered 21 days apart Well tolerated with mainly transient mild-to-moderate side effects Robust neutralizing antibody responses similar (GMT of 1,197.6) compared to control group 16 to 25 years old (GMT of 1,146.5) at one month post dose two, meeting the predefined immunobridging success criterion 13 1 These data are currently under review by the regulatory authorities and have been submitted for publication. The vaccine has received U.S. EUA for 5 to <12 year olds. A decision has not yet been issued in the E.U. BNT162B2 efficacy across age groups 16 years and older: 95% efficacy against symptomatic COVID-19 in Phase 3 pivotal trial with ~44,000 participants 16 years and older: 91% efficacy against symptomatic COVID-19 and 95.3% efficacy in preventing severe disease through to 6 months post second dose ● ● 12-15 year old children: 100% efficacy against COVID-19 infection and 100% efficacy against severe disease Further pediatric expansion Pediatric cohorts: 2-5 years and 6 months to 2 years of age Data expected in late Q4 2021 or early Q1 2022 ● 5-11 year old children: 90.7% efficacy against symptomatic COVID-19 infection and no cases of severe COVID-19 BIONTECH#14Clinical Strategy Supports Boosters and Platform Approach to Variants Clinical data supports a booster dose of the vaccine in adults or high risk populations to augment vaccine protection over time Clinical Trials Evaluating Booster Dose For Immunogenicity, Reactogenicity and Vaccine Efficacy 14 1 BNT162b2: 3rd dose Trials Evaluating Variant-Encoding Vaccines Support Flexible Platform Approach to Product Adaptation Safety & immunogenicity trial N=23 (Ph 1); N=~300 (Ph 2/3) First data published ¹ To date, no clinical evidence to advocate need to change vaccine to variant-specific version of vaccine. Platform approach preemptively prepares for the need, should it arise with a more severe/transmissible variant of concern. 3 Beta Variant-Encoding Vaccine: 3rd dose or naïve Safety & immunogenicity trial N=~300 (Ph 3); N=~300 (naïve) 2 BNT162b2: 3rd Dose Safety & Vaccine Efficacy trial N=~10,000 (Ph 3) Data in Q4 2021 Data in Q1 2022 4 Multivalent Delta + Alpha or Delta or Alpha Variant-Encoding Vaccines as 3rd dose or in naïve subjects Safety & immunogenicity trial N=~600; N= 300 (naïve) Data in Q4 2021 BIONTECH#1550% serum neutralizing titer Greater, Broader Neutralization and High Vaccine Efficacy Post Booster Dose for Protection Against Symptomatic Disease Greater, Broader SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 31 104 103 10² 101 103- 10² 101 1.0 10 10 Day 1 Pre-Vax 310 0.30 T 497 . 150 ${ 0.78 M1PD2 18-55 y/o n= 11/gp 0.27 387 241 103 0.48 1 Month 8 18-55 y/o n= 11/gp 1547 .. 0.69 1754 Day 7 Month 1 Day 7 Month 1 Post Dose 2 Post Dose 2 Post Dose 2 Post Dose 3 Post Dose 3 0.85 1202 M1PD3 0.73 1321 2119 •!• 1546 HE 44 1.0 10 10 Day 1 Pre-Vax 196 0.63 0.27 M1PD2 538 124 147 AA A A 65-85 y/o n=12/gp 0.29 261 HED 76 65-85 y/o n=12/gp 1613 0.49 15 1 Falsey AR, et al, N Engl J Med 2021:doi: 10.1056/NEJMC2113468 2 H Month 1 Day 7 Month 1 Month 8 Day 7 Post Dose 2 Post Dose 2 Post Dose 2 Post Dose 3 Post Dose 3 0.92 1479 0.67 M1PD3 1318 879 THE 0.77 2032 LOD 1567 *GMR Delta/WT PRNTWT PRNT Delta PRNTWT PRNT GMR Beta/WT LOD Beta Booster Dose of BNT162b2 demonstrates High Relative Vaccine Efficacy in Phase 3 Trial with ~9,000 Subjects Efficacy Endpoint First COVID-19 occurrence from ≥7 days after booster vaccination to <2 months after booster vaccination ● BNT162b2 (30µg) N=4695 n 5 Surveillance Time (n) 0.623 (4659) Placebo N=4671 n 109 Surveillance rVE Time (n) 0.604 (4614) 95.6 (95% CI) (89.3, 98.6) Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint rVE = relative vaccine efficacy of the BNT162b2 booster group relative to the placebo group (nonbooster) Well tolerated with adverse events similar to those demonstrated in clinical development program. No further safety signals observed. Relative vaccine efficacy consistent irrespective of age, sex, race, ethnicity, or comorbid conditions BIONTECH#16Booster Dose of BNT162b2 Restores High Levels of Vaccine Effectiveness and Prevents Against Severe Disease Across Diverse Population Groups, Globally Real world vaccine effectiveness post primary dose schedule Global data reflecting high vaccine effectiveness post primary regimen. Population analysis from the Israeli Ministry of Health data found BNT162b2 had a high level of VE across a range of outcomes ¹: ● ● Asymptomatic disease: Symptomatic disease: COVID-19 hospitalizations: Severe or critical hospitalization: Death: Vaccine effectiveness wanes with time post second dose regardless of variant of concern but vaccine efficacy preventing hospitalizations is maintained Analysis of more than three million US healthcare records² demonstrated that BNT 162b2 was 90% (95% CI 89-92) effective against hospitalization 16 91.5% (95% CI: 90.7-92.2) 97.0% (95% CI: 96.7-97.2) 97.2% (95% CI: 96.8-97.5) 97.5% (95% CI: 97.1-97.8) 96.7% (95% CI: 96.0-97.3) Adjusted estimated vaccine effectiveness (%) 100 90- 80- 70- 60- 50- 40 30- 20- 10 0 Variant Delta Other variant Failed sequencing <1 1 to <2 3 to <4 2 to <3 Time since full vaccination (months) z4 Real world evidence that a booster dose restores high levels of vaccine effectiveness for confirmed infections and severe disease ³ ● Fold reduction in rate of confirmed infections ● Risk Reduction at ≥12 days after 3rd Dose Booster Compared to Nonbooster by Age Group 25 20 15 10 5 0 16-29 30-39 40-49 Age Group At ≥12 days post booster dose vs non-booster cohort: 10-fold risk reduction of confirmed infection (8.8-17.6) across all age groups • 18.7-fold risk reduction in severe illness for ages 60+ ¹Haas E, et al. Lancet 2021; https://doi.org/10.1016/S0140-6736(21)00947-8 Tartof S et al. Lancet 2021 https://doi.org/10.1016/S0140-6736(21)02183-8; ³Bar-On et al 2021 MedRxiv [preprint] DOI: https://doi.org/10.1101/2021.10.07.21264626 50-59 60+ 22.0-fold risk reduction for severe illness for ages 40-60 14.7-fold risk reduction in COVID-19 associated deaths for ages 60+ BIONTECH#17Agenda Third Quarter 2021 Highlights 17 COVID-19 Vaccine Update Oncology Pipeline Update Financial Results Corporate Update & Outlook BIONTECH#18Potential To Tackle Multiple Diseases With Different Therapeutic Modalities iNeST / Fix Vac mRNA Cancer Vaccines Induces multi-specificity, multi-valency, high tumor-antigen specific cell responses with unprecedented potency . 4 Phase 2 randomized trials (2 iNeST and 2 Fix Vac) Cell Therapies Next Gen CAR-T Cell / Neoantigen-based T Cell / Personalized TCR-T Cell Therapy ● 2 Phase 1 FIH trials started in Feb. and Apr. 2021 ● Targeting Cancer Targeted Cancer Antibodies ● Antibodies Novel cancer cell surface targets for underserved high medical need cancers CA 19-9 antibody in 1L pancreatic cancer in Phase 1/2 trial Immunomodula Small Molecule Immunomodulators TLR-7 Agonist ● Potently modulates innate immunity Phase 1 trial Clinical progress across all platforms ● Bispecifics / Hexabody Next-generation checkpoint inhibitors to address a broad range of cancers Phase 1/2 trials of 2 bispecific antibodies ● ● Next Generation Immunomodulators Ribocytokines, RiboMabs mRNA encoded cytokines or antibodies with potential for improved properties and half life Potential to amplify vaccines and CPIs . 2 Phase 1 FIH Ribocytokine trials 18 CAR, Chimeric antigen receptor; TCR, T Cell receptor; FIH, First-in-human; CA 19-9: Cancer antigen 19-9; 1L, first-line; TLR-7, Toll-like receptor 7; CPI, Check-point Inhibitor Ribologicals BIONTECH#19Strong Clinical Execution: On Track To Achieve 2021 Corporate Milestones Eight clinical trial initiations in 2021, including three Phase 2 and five first-in-human studies 4 Randomized Phase 2 Trial Starts 19 ● ● ● ● ● 5+ Trial Updates E ● BNT162b2: Multiple updates Additional data disclosures at SITC*: BNT111 BNT112 • BNT221 (pre-clinical) Corporate Milestones - SITC*: BNT311 BNT312 BNT211 BNT411 * SITC: November 10-14, 2021 - abstract embargo lift Nov. 9, 8 am ET BNT111 ✓BNT113 ✔BNT122 ● BNT311 Q4 2021 NEW 6 First-in-human Phase 1 Trial Starts ✓BNT211 - CARVac (Cell Therapy) BNT221 - NEOSTIM (Cell Therapy) BNT151 - Ribocytokine (mRNA) ✓BNT152+153 - Ribocytokine (mRNA) ● TOPP BNT161: Influenza vaccine (license Pfizer) BNT141 - Ribomab (mRNA) - Q4 2021 BNT142 - Ribomab (mRNA) - 1H 2022 BIONTECH#20Autogene cevum eran (BNT122): First Patient Dosed in Phase 2 Clinical Trial in Adjuvant Colorectal Cancer Randomized, Phase 2 trial evaluating autogene cevumeran* in the adjuvant treatment of circulating tumor DNA positive, surgically resected Stage II (high risk)/Stage III colorectal cancer ● Colorectal cancer is second deadliest cancer worldwide ¹, 5 year OS in regional disease is 71% ² SoC in Stage II (high risk) and Stage III CRC after removal of the primary tumor and adjuvant chemotherapy is watchful waiting ctDNA is a marker for minimal residual disease and thus can identify patients at high risk of disease recurrence³,4 In ctDNA-positive, Stage 2 (high risk) and Stage 3 CRC post AdCTx, duration of disease free survival is 6 months5 Challenge in Adjuvant Setting in Stage 2 (high risk) and Stage 3 Colorectal Cancer: Residual cancer cells may remain. Stage II (high risk) and Stage III colorectal cancer 20 Surgery CT scan Adjuvant chemo given to all patients OS, Overall Survival; CRC, Colorectal Cancer; SoC, Standard of Care; ctDNA, circulating tumor DNA; AdCTx, adjuvant chemotherapy No Residual Disease Microscopic Residual Disease ¹WHO factsheet on cancer. 2018; 2Seer database; ³Fan et al, PLoS One 2017; 4Loupakis et al. 2021, JCO Precision Oncology; "Reinert et al., JAMA Oncology, 2019 *Autogene cevumeran is partnered with Genentech 50% Cured by surgery alone 20% Cured by chemo on top of surgery 30% Recur despite surgery + chemo BIONTECH#21Clinical Data Showing at SITC 2021 Provides Further Proof-of-Concept Of Therapeutic Platforms & Support Continued Advancement 21 6 PROGRAM Clinical Data Presentations across 4 THERAPEUTIC Platforms mRNA Cancer Vaccines Engineered Cell Therapies Next Generation Checkpoint Immunomodulators Small Molecule Immunomodulator 1 LATE Breaker CAR-T therapy: CARVac (BNT211) 6 Clinical Programs Showed Promising Signs of Clinical Activity and Favorable Safety Profiles 2 ORAL Presentations Next Gen Immunomodulator (BNT312) CLDN-6 CARVAC (BNT211) .. 5 POSTERS FixVac (BNT111) Fix Vac (BNT112) iNeST (BNT122) sitc TLR-7 agonist (BNT411) Bispecific antibody (BNT311) Additional Data to be Presented at SITC BIONTECH#22SITC 2021 - BNT111 Phase 1: Strong Immunogenicity and Promising Clinical Activity in Cutaneous Melanoma Patients with Evidence of Disease and No Evidence of Disease FixVac off-the-shelf mRNA vaccine targeting 4 tumor-associated shared antigens Open-label, multicenter non-randomized trial in patients with pretreated, Stage III or IV cutaneous melanoma (n=115) ● ● 22 BNT111 Monotherapy 6 weekly and 2 biweekly injections (7 dose escalation cohorts and 3 expansion cohorts) Favorable Safety profile Most common treatment-related AEs: Mostly mild-to-moderate flu-like symptoms Similar safety profile between evidence of disease & no evidence of disease populations Low rate of related Serious AE Low rate of TEAE of Grade 23 nature¹ An RNA vaccine drives immunity in checkpoint- inhibitor-treated melanoma Ugur Sahin, Petra Oehm, [...]Özlem Türeci •O Data cutoff: May 24, 2021. AEs, adverse events; TEAE, treatment-emergent adverse events; CI, confidence interval ¹Sahin U, et al. Nature 2020; 585:107-112 (https://www.nature.com/articles/s41586-020-2537-9) No evidence of disease (n=33) Evidence of disease (n=38) Long-term follow up To be presented at SITC Continued treatment phase Previously reported in Nature ¹ CD4+ and CD8+ T cell responses Frequent high magnitude T cell responses; comparable between evidence of disease & no evidence populations In no evidence of disease patients 95% CI: 7.0-not reached Ex vivo ELISpot response against ≥1 tumor-associated antigen in: 14/22 (63.6%) evidence of disease patients 19/28 (67.7%) no evidence of disease patients Substantial fraction of de novo induced responses Median disease-free survival 34.8 months BIONTECH#23BNT112 Phase 1/2: Fix Vac Off-the-Shelf mRNA Vaccine as Monotherapy and in Combination with PD-1 Inhibitor in Patients with Prostate Cancer BNT112 targets 5 prostate cancer tumor-associated shared antigens Part 1: Dose titration Monotherapy Only patients with mCRPC Metastatic castration-resistant ● ● 23 prostate cancer or localized prostate cancer Patients All patients Stage 4 at diagnosis Median age 68 years ● ● BNT112 mCRPC (n=9) 11 patients treated with monotherapy 3 with BNT112 + cemiplimab REDR 1:1 Part 2: Expansion cohorts Monotherapy and combination therapy mCRPC and LPC ● Did not meet DLT definition according to Safety Review. Committee BNT112 + cemiplimab mCRPC (n=33) BNT112 mCRPC (n=33) AEs mostly mild-to-moderate Most common related AEs: pyrexia and hypertension Dose reduction due to Grade 3 hypertension in 2 patients. Patients recovered within 24 hours 8 serious AEs in 5 patients unrelated to BNT112 No safety signals of concern 1:1 BNT112 + cemiplimab LPC (n=20) BNT112 LPC (n=20) Vaccine induced immune responses All ELISpot-evaluable patients (n=7) showed vaccine- induced immune response All 5 BNT112 tumor-associated antigens are immunogenic T cell responses to each antigen in at least 2 of 7 evaluable patients Signs of anti-tumor activity Decreased prostate-specific antigen (PSA) levels in 2 patients with monotherapy Data cutoff: 22 June 2021; mCRPC, metastatic castration-resistant prostate cancer; LPC, localized prostate cancer; REDR, recommended dose expansion range; AE, adverse event; DLT, dose-limiting toxicity; PSA, prostate-specific antigen ....... BIONTECH#24BNT211: Phase 1/2 trial evaluating next Generation CAR-T Targeting Claudin-6 with CARVac in Solid Tumors CAR-T cell therapy + CARVac RNA Vaccine to amplify CAR-T cell in vivo BNT211 CAR Structure ● ● ● 24 New 2nd generation CAR directed against CLDN6, a new highly cancer cell specific carcino-embryonic antigen CLDN6 is expressed in multiple solid cancers with high medical need tumor types CARVac drives in vivo expansion, persistence and efficacy of CAR-T Patients with CLDN6-positive relapsed or refractory advanced solid tumors (up to 36 patients) .. High CLDN6 expression extracellular intracellular aCLDN6 scFv CD8 hinge 4-1BB CD32 Part 1 CLDN6 CAR-T dose escalation (3 dose levels) Part 2 CLDN6 CAR-T + CLDN6 CARVac dose escalation RP2D CLDN6 not present in healthy tissues 0 CLDN6 expressed in multiple cancers Ovarian Part 3 Expansion Cohorts Ovarian Cancer Testicular Cancer Endometrial Cancer ● ● ● ● ● Testicular ● Lung Cancer Gastric Cancer Tumors NOS CLDN6, Claudin-6; CAR-T cells, chimeric antigen receptor engineered T cells; scFv, single chain variable fragment; RP2D, recommended Phase 2 dose; NOS, not otherwise specified Reinhard K, et al. Science 2020; 367:446-453 Lung BIONTECH#25SITC 2021 - BNT211 Phase 1/2 trial: Favorable Safety Profile and Encouraging Signs of Efficacy for CLDN6 CAR-T Cells +/- CARVac ● ● 25 Heavily pretreated patients Testicular, ovarian, endometrial cancer, CUP & soft-tissue sarcoma 8 patients treated ● CLDN6 CAR-T cells monotherapy: 3 patients treated. with DL1 and 2 with DL2 CLDN6 CAR-T + CARVac: 3 patients treated with DL1 No DLTs or serious drug-related AEs with monotherapy Manageable cytokine release. syndrome No signs of neurotoxicity with monotherapy Transient and moderate elevations of IL-6 and CRP in patients without clinical CRS symptoms Transient flu-like symptoms in patient with CLDN6 CAR-T + CARVac, resolving within 24 hours Robust CAR-T cell engraftment Enhanced expansion of CAR-T cells in 2 patients with liver metastases Elevated ALT, AST and AP levels • Total bilirubin unaffected ● Signs of clinical activity 6-week tumor assessment available for 5 of 8 patients ● 4 SD (3 transitioned into PD after an additional 6-18 weeks) and 1 PD • 3 patients showed initial tumor shrinkage according to RECIST1.1 (reduction of target sum: -18%, -21% and -27% Data cutoff: July 23rd 2021; CUP, cancer of unknown primary; DL, dose level; DLT, dose toxicity; AE, adverse event; ALT, alanine AP, alkaline phosphatase; AST, aminotransferase; CAR-T cells, chimeric antigen receptor engineered T cells; CRP, C-reactive protein; CRS, cytokine release syndrome; CUP, cancer of unknown primary; DL, dose level; IL-6, interleukin 6; BIONTECH PD, progressive disease; RECIST, Response Evaluation Criteria In Solid Tumors; SD, stable disease.#26BNT311 Phase 1/2: First-in-Human Study of DuoBody-PD-L1x4-1BB, A Next-Generation Bispecific Antibody Next Generation Immunomodulator Bispecific antibody* designed to induce an antitumor immune response by simultaneous and complementary PD-L1 26 blockade and conditional 4-1BB stimulation Mechanism of action of FC-silenced DuoBody-PD-L1x4-1BB Patients with metastatic, unresectable solid tumors who are not candidates for SoC N~61 T Cell TCR MHC-I/II Open-label, dose-escalation trial with expansion cohorts to evaluate safety Part 1 BNT311 dose escalation 4-1BB PD-L1* (tumor cell/APC) Expansion dose 100 mg PD-1 DuoBody-PD-L1x4-1BB PD-L1 DuoBody-PD-L1x4-1BB Tumor Cell Antigen-presenting cell T cell Myeloid cell Natural Killer cell Macrophage Expansion Cohorts n = up to 40 per cohort SoC, Standard of Care; NSCLC, Non-small Cell Lung Cancer; TNBC, Triple-negative breast cancer; SCCHN, Squamous cell carcinoma of the head and neck; *BNT 311 (GEN 1046) is partnered with Genmab based on 50/50 sharing of costs and profits NSCLC, Urothelial cancer, Endometrial cancer, TNBC, SCCHN, Cervical cancer 9 expansion cohorts are ongoing LOCAL LYMPH NODES APC NK TUMOR BIONTECH#27SITC 2021 - BNT311 Phase 1/2: Pharmacodynamic Effects Consistent with Proposed Mechanism of Action in Patients with NSCLC who Progressed on PD-L1 Therapy Peripheral and tumoral immune activity in expansion cohort of patients with PD-L1-R/R NSCLC 27 ● Positive pharmacodynamics responses Induction of cytokines (IFN-y & CXCL9/10) Expansion of CD8+ effector memory T cells & activated NK cells 5 patients with confirmed partial response Greater induction of IFN-y, CXCL9/10 and activated NK cells in responders vs non-responders 6 Relationship between disease control and PD-L1 expression, as well as time from last prior anti-PD-1 therapy Higher disease control rates in patients with prior anti-PD-1 therapy within 8 months from first dose of study drug Patients with tumor reduction mainly PD-L1+ tumors Phase 2 trial of BNT311 as monotherapy and in combination with pem brolizumab in R/R metastatic NSCLC expected to start in Q4 2021 CXCL, chemokine (C-X-C motif) ligand; IFN, interferon; NK, natural killer; NSCLC, non-small cell lung cancer; R/R, relapsed/refractory BIONTECH#28BNT312 Phase 1/2: First-in-Human Study of DuoBody-CD40x4-1BB, A Next-Generation Bispecific Antibody Next Generation Immunomodulator Bispecific antibody* combines targeting and conditional activation of CD40 and 4-1BB on immune cells Potential to enhance priming and (re-)activation of tumor-specific immunity ● Patients with relapsed or refractory, advanced or metastatic solid tumors who are not candidate for SoC N~50 ..... 28 Mechanism of action of DuoBody-CD 40x4-1BB T BNT312 dose escalation APC TCR Expansion dose 100 mg MHC-I/II 4-1BB APC CD40 į T Cell Open-label dose-escalation trial with expansion cohorts to evaluate safety and anti-tumor activity Part 1 DuoBody-CD40x4-1BB Tumor Cell Antigen-presenting cell T cell Myeloid cell Natural Killer cell Macrophage DuoBody-CD40x4-1BB SoC, Standard of Care; NSCLC, Non-small Cell Lung Cancer; PDAC, Pancreatic ductal adenocarcinoma; HNSCC, Head and neck squamous cell carcinoma *BNT312 (Gen1042) is partnered with Genmab based on 50/50 sharing of costs and profits LOCAL LYMPH NODES Expansion Cohorts n = up to 40 per cohort Metastatic Melanoma, NSCLC, Colorectal Cancer, PDAC, HNSCC Expansion cohorts in melanoma and NSCLC are currently recruiting NK APC APC TUMOR Safety follow-up visits BIONTECH#29SITC 2021 - BNT312 Phase 1/2: Favorable Safety Profile, Biologic Activity and Early Antitumor Activity Observed with Monotherapy ● ● ● BNT312 monotherapy in dose escalation cohort: 50 patients 29 Median 57 years old Most common cancer types . Colorectal (22%) Melanoma (20%) NSCLC (8%) Median of 2.5 treatment cycles C max observed shortly after end of infusion ● ● ● Treatment-related AEs occurring in ≥10% of patients Fatigue Pyrexia Nausea Maximum tolerated dose not reached Transaminase elevation ● All grades 22% 16% 10% 10% Grade 23 One DLT of elevated transaminases (grade 4) Occurred at 200 mg dose Resolved upon corticosteroid administration • No drug-related grade 23 thrombocytopenia 6% Biological activity consistent with mechanism of action Increased levels of: ● Further Evaluation: 100 mg every 3 weeks was identified as the expansion dose Peripheral monocyte and DC cytokines (IFN-Y, TARC) CD8+ total and effector memory T cells 51% of patients (n=25/49) achieved disease control Defined as best overall response of complete/partial response and stable disease 2 confirmed partial responses (melanoma and neuroendocrine lung cancer) Data cutoff:1 July 2021. Cmax, peak serum concentration; AE, adverse event; DC, dendritic cell; DLT, dose-limiting toxicity; IFN-y, interferon gamma; TARC, thymus- and activation-regulated chemokine; NSCLC: Non-small-cell lung cancer BIONTECH#30SITC 2021 - BNT411 Phase 1/2: Tolerable Safety Profile and Encouraging Pharmacodynamic Signals with Monotherapy at All Doses Small molecule immunomodulator designed to activate both the adaptive and innate immune system through the TLR-7 pathway 30 BNT411 monotherapy: 11 patients Median age 62 years Previously received 2-5 systemic cancer therapies 5 of 8 DLs cleared in Part 1 A ● Solid tumors N-60 Dose escalation ● BNT411 monotherapy Patients with metastatic or unresectable solid tumors (ECOG 0 or 1) that have exhausted available treatment options BNT411 + chemotherapy and checkpoint inhibition Patients with chemotherapy-naïve Tolerable safety profile and no DLTS tested to-date ES-SCLC Only drug-related AEs: Pyrexia (n=2), grades 1 & 3 (non-serious) Anemia (n=2), grades 1 & 2 Expansion cohorts Preliminary biological activity consistent with mechanism of action Plasma cytokine levels were highest. at DL5 (2.4 µg/kg) in 3/4 of patients Interferon-y induced protein (IP10) increased 2.7-9.2-fold Data cutoff:1 July 2021. ECOG, Eastern Cooperative Oncology Group; ES-SCLC, extensive-stage small cell lung cancer; AE, adverse event; DL, dose level; DLT, dose-limiting toxicity BIONTECH#31Agenda Third Quarter 2021 Highlights 31 Oncology Vaccine Update Pipeline Update COVID-19 Financial Results Corporate Update & Outlook BIONTECH#32Q3 2021 and 9M 2021 Financial Results (unaudited) - Profit or Loss Three months ended September 30, 2021 32 (in millions, except per share data)* Research & development revenues Commercial revenues Total revenues Cost of sales Research and development expenses Sales and marketing expenses General and administrative expenses Other operating income less expenses Operating income / (loss) Finance income less expenses Income taxes Profit (loss) for the period Earnings per share Basic profit/ (loss) for the period per share Diluted profit/ (loss) for the period per share €47.2 6,040.1 €6,087.3 (1,211.4) (260.4) (10.5) (68.2) 186.7 €4,723.5 (56.1) (1,456.4) €3,211.0 €13.14 €12.35 2020 €59.7 7.8 €67.5 (6.8) (227.7) (4.3) (23.5) 8.4 €(186.4) (21.1) (2.5) €(210.0) €(0.88) €(0.88) *Numbers have been rounded, numbers presented may not add up precisely to the totals and may have been adjusted in the table context. Presentation of the interim consolidated statements of profit or loss has been condensed. Nine months ended September 30, 2021 €96.1 13,348.1 €13,444.2 (2,328.3) (677.7) (32.5) (154.9) 333.3 €10,584.1 (251.6) (3,206.2) €7,126.3 €29.22 €27.46 2020 €113.4 23.5 €136.9 (18.3) (388.0) (7.8) (58.1) 8.7 €(326.6) (24.8) (0.3) €(351.7) €(1.51) €(1.51) BIONTECH#33Q3 2021 and 9M 2021 COVID-19 Vaccine Deliveries Drove Revenue Growth €6,021.6m 33 COVID-19 vaccine revenues €6,040.1m €4,358.5m €1,350.8m €312.3m €18.5m Q3 2021 €13,348.1m €10,202.7m €2,586.2m €514.3m -€44.9m Commercial revenues - identified revenue streams COVID-19 vaccine revenues €13,303.2m 9M 2021 *Represents an estimated figure based on preliminary data shared between Pfizer and BioNTech. Changes in share of the collaboration partner's gross profit will be recognized prospectively. Graphic is for illustration only. Share of gross profit from COVID-19 vaccine sales in the Pfizer and Fosun territory (net position) and sales milestones (€17.0m for Q3 2021 and €432.8m for 9M 2021, respectively)* Direct COVID-19 vaccine sales to customers in BioNTech's territory Sales to collaboration partners of products manufactured by BioN Tech Other sales (mainly JPT and IMFS business) BIONTECH#34Updated Outlook for the 2021 Financial Year Update on COVID-19 Vaccine Planned Deliveries for the 2021 Financial Year Estimated BioN Tech COMIRNATY/COVID-19 vaccine revenues for the full 2021 financial year based on up to 2.5 billion doses: €16 billion to €17 billion* ● Planned 2021 Financial Year Expenses and Capex* Previous cost guidance maintained for the full 2021 financial year R&D expenses SG&A expenses Capital expenditure 34 €950 million - €1,050 million €250 million - €300 million €175 million - €225 million Further ramp-up of R&D investment in Q4 2021 planned to expand and accelerate the pipeline development Ranges reflect current base case projections Estimated 2021 Financial Year Tax Assumptions BioNTech Group estimated annual effective income tax rate *Figures have been estimated at constant foreign exchange rates. -31% BIONTECH#35Agenda Third Quarter 2021 Highlights 35 Oncology Vaccine Update Pipeline Update COVID-19 Financial Results Corporate Development & Outlook BIONTECH#36Expansion into New Class of Precision Antibacterials with PhagoMed Acquisition D ........ 36 ● ● ● ● ● ● PhagoMed: based in Vienna, Austria Pioneering new class of precision antibacterials called synthetic lysins. Lysins are highly bactericidal phage-derived enzymes that cleave the bacterial cell wall Potential to address difficult to target pathogens & global challenge of antimicrobial resistance. Lysin Builder in silico technology platform based on proprietary algorithms Designed to rapidly produce recombinant natural lysins against a wide range of pathogens Optimization for potency, stability and manufacturing yield Total consideration can reach up to €150.0 m consisting of upfront consideration of €50.0 m (less) acquired debt) with the possibility of the selling shareholders earning up to an additional ~ €100.0 m Transaction closed in Q3 Forms BioNTech's new R&D hub for precision antibacterials operating as BioN Tech R&D Austria mRNA Vaccines Acquisition expands Infectious Disease Toolkit: | mRNA Encoded Antibodies .... Precision Anti-bacterials BIONTECH#37Expanding our Capabilities and Pipeline in Infectious Diseases ● ● COVID-19 37 mRNA COVID-19 vaccine More than 2 billion doses shipped world-wide Addressing Infectious Diseases with Significant Global Impact ● 8 Seasonal Flu vaccine: Phase 1 trial initiated Q3 • Licensed to Pfizer Eligible for milestone payments and royalties through Pfizer agreement HIV Multiple product candidates in Preclinical development Influenza Vaccines and Ribologicals Collaboration with Bill & Melinda Gates Foundation ● ● mRNA-based Malaria vaccine candidate Malaria Expected Phase 1 start: 2H 2022 • Sustainable end-to-end vaccine supply solutions in Africa planned 5 Additional Non-disclosed Programs Multiple product candidates in preclinical development Vaccines and Ribologicals ob Tuberculosis vaccine candidate Expected Phase 1 start: 2H 2022 • Collaboration with Bill & Melinda Gates Foundation Bacterial Infections New class of precision antibacterials in the form of synthetic lysins Potential to address wide range of pathogens Tuberculosis BIONTECH#38Oncology Pipeline: 15 Product Candidates in 19 Ongoing Clinical Trials Drug class mRNA Antibodies SMIM ³ 38 Platform Fix Vac (fixed combination of shared cancer antigens) iNeST (patient specific cancer antigen therapy) Intratumoral Immunotherapy RiboCytokines (mRNA-encoded Cytokines) Next-Gen CP² Immunomodulators Targeted Cancer Antibodies Toll-Like Receptor Binding CAR-T Cells Cell Therapies Neoantigen-based T cell therapy Product Candidate BNT111 BNT112 BNT113 BNT115 autogene cevumeran (BNT122) SAR441000 (BNT131) BNT151 BNT152 + BNT153 GEN1046 (BNT311) GEN1042 (BNT312) BNT321 (MVT-5873) BNT411 BNT211 BNT221 (NEO-PTC-01) Indication (Targets) advanced melanoma prostate cancer HPV16+ head and neck cancer¹ ovarian cancer¹ 1L melanoma adjuvant colorectal cancer solid tumors solid tumors (IL-12sc, IL-15sushi, GM-CSF, IFN a) solid tumors (optimized IL-2) solid tumors (IL-7, IL-2) solid tumors (PD-L1x4-1BB) solid tumors (CD40x4-1BB) pancreatic cancer (sLea) solid tumors (TLR7) solid tumors (CLDN6) solid tumors Preclinical Phase 1 ¹BNT113 and BNT115 are currently being studied in investigator-initiated Phase 1 trials. 2Checkpoint Inhibitor. ³Small Molecule Immunomodulators. Phase 2 Phase 3 Rights Collaborator fully-owned fully-owned fully-owned fully-owned Genentech (global 50:50 profit/loss) Sanofi (global profit/loss share) fully-owned fully-owned Genmab (global 50:50 profit/loss) fully-owned fully-owned fully-owned fully-owned BIONTECH#39Poised to Accelerate Our Transformation 39 Rapidly advance pipeline 15 Oncology product candidates in 19 ongoing clinical trials 3 Phase 2 trials started in 2021 5 First-in-human trial starts in 2021 6 program updates at SITC Expansion into new class of Precision Antibacterials KA ку Expand integrated infrastructure Expansion of team to more than 2,800 professionals globally Significant investments in digital Further scale-up of Marburg mRNA manufacturing site Planning further mRNA manufacturing sites in Africa and Singapore Increase global footprint Continued expansion in U.S. with acquisition of cGMP Kite Cell Therapy manufacturing facility Planning to establish Southeast Asia headquarters in Singapore. BioNTech R&D Austria established through Phago Med acquisition ........ ........ Building long-term value for patients, investors and and society as we advance our vision of harnessing the immune system's full potential to fight human disease BIONTECH#40BIONTECH An der Goldgrube 12 55131 Mainz Germany M: [email protected]